XXXX after kidney transplantation: course of @entity281 and outcome in relation to blood viral load and immune recovery.

@entity1 @entity9504 @entity2348 @entity281 @entity7076 @entity813
Information on the clinical spectrum and management of @entity9504 after kidney transplantation is limited. From April 2007 to April 2010, 17 kidney transplant recipients were diagnosed with @entity9504 . The median time to @entity281 was 5 (range, 2-300) weeks after transplantation. Of the 17 @entity1 , 13 (76.5%) presented early, within 3 months posttransplant, and four (23.5%) presented late, more than 3 months after transplant. Besides urinary tract, involvement of other organs was common (63.6%) among @entity1 with @entity9504 . Despite reduction of immunosuppression, six @entity1 subsequently had a rise in the level of blood viral load, mostly within a week after diagnosis. However, only three (27.3%) @entity1 with @entity281 developed disease progression. Compared to the late @entity281 group, @entity1 with @entity281 had significantly lower absolute lymphocyte counts at week 1 (p = 0.01) and 3 (p = 0.002) after diagnosis. Four @entity1 received intravenous @entity7076 . At 6-month follow-up, 10 (90.9%) @entity1 had reversible @entity813 . Only one (5.7%) died from @entity2348 . @entity9504 is a significant complication following kidney transplantation. Early case recognition with reduction of immunosuppression is critical. Serial blood adenovirus viral loads and assessment of lymphocyte recovery are also useful in monitoring the course of @entity281 .
